CLINICAL_TRIALS
trial_result
· 2017-07-02
Clinical Trial Update: A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy [Phase 2]
Summary
Phase 2 randomized, double-blind, placebo-controlled dose ranging study of repeat doses of AA4500 for edematous fibrosclerotic panniculopathy has completed with…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Endo Pharmaceuticals | Conditions: Edematous Fibrosclerotic Panniculopathy (EFP) | Phase 2 | Status: COMPLETED | Results posted: 2017-07-02